Your browser doesn't support javascript.
loading
Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang, Xuelong; Yang, Ping; Yuan, Shuai S; Wang, William W B.
Afiliação
  • Wang X; BARDS, Merck & Co, Rahway, New Jersey, USA.
  • Yang P; BARDS, MSD China Holding Co, Ltd, Shanghai, China.
  • Yuan SS; Oncology Statistics, GSK, Collegeville, Pennsylvania, USA.
  • Wang WWB; BARDS, Merck & Co, Rahway, New Jersey, USA.
J Biopharm Stat ; 33(4): 476-487, 2023 Jul 04.
Article em En | MEDLINE | ID: mdl-36951445
ABSTRACT
Defining the right question of interest is important to a clinical study. ICH E9 (R1) introduces the framework of an estimand and its five attributes, which provide a basis for connecting different components of a study with its clinical questions. Most of the applications of the estimand framework focus on efficacy instead of safety assessment. In this paper, we expand the estimand framework into the safety evaluation and compare/contrast the similarity and differences between safety and efficacy estimand. Furthermore, we present and discuss applications of a safety estimand to oncology trials and pooled data analyses. At last, we also discuss the potential usage of safety estimand to handle the impacts of COVID-19 pandemic on safety assessment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Limite: Humans Idioma: En Revista: J Biopharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Limite: Humans Idioma: En Revista: J Biopharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos